KURA ONCOLOGY INC

Insider moves in Kura Oncology: Chief Legal Officer’s 8,442‑share sell is routine tax‑cover activity, not a sign of trouble—focus on clinical progress instead.

Investor insight: KURA Oncol buy‑back signals CEO confidence in a pipeline for pancreatic and blood cancers, amid share price swings.

CEO Troy Edward buys 100k Kura Oncology shares, boosting confidence in the biotech’s pipeline and signaling a bullish outlook.

Inside KURA Onco’s block sale: COO Teresa Brophy sells 31,487 shares at $12.63 under a Rule 10b5‑1 plan—steady divestment, not distress.

Insider buy: Kura Oncology CEO Troy Edward purchases 100k shares after Q2 earnings beat, signaling confidence amid potential upside and dilution risk.

Insider sale of 10,000 Kura Oncology shares at $11.00 shows routine, plan‑based trading; investors should focus on clinical milestones, not individual trades.

Insider sales by Kura Oncology’s execs, including a May 18 sale, reveal a balanced buying‑selling strategy rather than panic, highlighting the need to focus on clinical milestones for future value.